Market Place
Sourcing Support
Mabwell Reveals Pre-clinical 7MW4811 Data at World ADC Conference
08 Nov 2024 //
PR NEWSWIRE
Mabwell`s 9MW2821 Approved For Phase III Trial In Urothelial Carcinoma
26 Aug 2024 //
PR NEWSWIRE
Mabwell`s Nectin-4 ADC Approved For Phase III Trial In Cervical Cancer
23 Aug 2024 //
PR NEWSWIRE
Mabwell`s ADC 9MW2821 Gets Breakthrough Status From China`s NMPA
12 Aug 2024 //
PR NEWSWIRE
Mabwell Receives NMPA Approval For ADC Clinical Trial In TNBC
15 Jul 2024 //
PR NEWSWIRE
Mabwell 9mw2821 Asco Update: Clinical Data And Progress Details
24 May 2024 //
PR NEWSWIRE
Mabwell Announces Trial Of 9MW2821 In Triple-Negative Breast Cancer
13 May 2024 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to 9MW2821
07 May 2024 //
PR NEWSWIRE
Mabwell to Present 9MW2821 Solid Tumor Data at ASCO 2024
25 Apr 2024 //
PR NEWSWIRE
Mabwell: Innovative Drugs Preclinical Data At AACR 2024
16 Apr 2024 //
PR NEWSWIRE
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
08 Apr 2024 //
PR NEWSWIRE
Mabwell Presented IDDC™ Platform Technology and ADC Development a ADC
20 Mar 2024 //
PR NEWSWIRE
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC
19 Mar 2024 //
PR NEWSWIRE
Mabwell to Present Pre-clinical Results at the 2024 AACR Annual Meeting
12 Mar 2024 //
PR NEWSWIRE
Mabwell to Present ADC Platform IDDC™
11 Mar 2024 //
PR NEWSWIRE
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer
08 Mar 2024 //
PR NEWSWIRE
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar
21 Feb 2024 //
PR NEWSWIRE
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
20 Feb 2024 //
PR NEWSWIRE
New Drug Application of Mabwell`s 8MW0511 for Injection Accepted by NMPA
19 Dec 2023 //
PR NEWSWIRE
Mabwell Announces CDE Approval of Novel Nectin-4 Targeting ADC for PIII Trial
11 Dec 2023 //
PR NEWSWIRE
Oral Presentation of Mabwell`s 9MW2821 at 2023 ESMO
25 Oct 2023 //
PR NEWSWIRE
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023
23 Oct 2023 //
PR NEWSWIRE
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4
28 Sep 2023 //
PR NEWSWIRE
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration
08 Sep 2023 //
PR NEWSWIRE
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
25 Jul 2023 //
PR NEWSWIRE
Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
21 Jul 2023 //
PR NEWSWIRE
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
18 Jul 2023 //
PR NEWSWIRE
Mabwell Publishes the Study Results on Its Nectin-4 Targeting ADC
15 Jun 2023 //
PR NEWSWIRE
Mabwell Announces the U.S. FDA approval of 9MW3811 for IND
15 Jun 2023 //
PR NEWSWIRE
China`s First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
07 Apr 2023 //
PR NEWSWIRE
Mabwell Launched First in human Trial of Its Drug 9MW3011
14 Mar 2023 //
PR NEWSWIRE
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND
28 Feb 2023 //
PR NEWSWIRE
Mabwell Announces the NMPA approval of 9MW3011 (FIC) for IND
03 Jan 2023 //
PRESS RELEASE
